|
There are some safety issues to be considered when using postoperative 90Sr βirradiation. First of all, the eyeball should be fixed during the radiotherapy. Eye fixation can reduce the incidence of scleral necrosis. The second safety issue is that the cornea should be protected, when the affected area is covered with the 90Sr applicator. Third, the dosage of 90Sr βirradiation and treatment time should be precise. The last but not the least, the patient should be examined everyday carefully for 10 days in order to avoid occurrence of serious side effects. If the patient has feeling of pain or chemosis, we should be extremely cautious to carry out the treatment.
In this study, we also analyzed the factors related to local recurrence of the pterygium, after surgery and 90Sr βirradiation. The reason for high recurrence rate of pterygium in younger patients (<40 years) could be that younger persons have more opportunity to exposure to ultraviolet radiation and stronger ability of fibroblast proliferation. The healthy Bowmans membrane seems to act as a barrier to the in growth of conjunctival tissues. In patients of recurrent pterygium with previous history of surgery, the cause for recurrence could be the destruction of normal limbal structure and the changes in the tear film. There were some reports suggesting a high recurrence in males[11]. In contrast, our data didnt show statistically difference between male and female. However, our study is a retrospective analysis, and prospective studies are required to overcome the selection bias and prove this point.
【参考文献】
1 Ang LP, Chua JL, Tan DT. Current concepts and techniques in pterygium treatment. Curr Opin Ophthalmol 2007;18(4):308313
2 Anduze AL, Merritt JC. Pterygium: clinical classification and management in Virgin Islands. Ann Ophthalmol 1985;17(1):9295
3 Chen PP, Ariyasu RG, Kaza V. A randomized trial comparing mitomycin C and conjunctival autograft after excision of primary pterygium. Am J Ophthalmol 1995;120(2):151160
4 Panda A, Das GK, Tuli SW, Kumar A. Randomized trial of intraoperative mitomycin C in surgery for pterygium. Am J Ophthalmol 1998;125(1):5963
5 Smith RA, Dzugan SA, Kosko P. Postoperative beta irradiation for control of pterygium. J Miss State Med Assoc 2001;42(6):167169
6 Raiskup F, Solomon A, Landau D, Ilsar M, FruchtPery J. Mitomycin C for pterygium: long term evaluation. Br J Ophthalmol 2004; 88(11):14251428
7 Reisman D, McFadden JW, Lu G. Loss of heterozygosity and p53 expression in pterygium. Cancer Lett 2004;206(1):7783
8 Tan DT, Tang WY, Liu YP, Goh HS, Smith DR. Apoptosis and apoptosis related gene expression in normal conjunctiva and pterygium.
Br J Ophthalmol 2000;84(2):212216
9 Pajic B, Greiner RH. Long term results of nonsurgical, exclusive strontium/yttrium90 betairradiation of pterygia. Radiother Oncol 2005;74(1):2529
10 Constable PH, Crowston JG, Occleston NL, Cordeiro MF, Khaw PT. Long term growth arrest of human Tenons fibroblasts following single applications of beta radiation. Br J Ophthalmol 1998;82(4):448452
11 Isohashi F, Inoue T, Xing S, Eren CB,Ozeki S, Inoue T. Postoperative irradiation for pterygium: retrospective analysis of 1,253 patients from the Osaka university hospital. Strahlenther Onkol 2006;182(8):437442
12 Mourits MP, Wyrdeman HK, JurgenliemkSchulz IM, Bidlot E. Favorable longterm results of primary pterygium removal by bare sclera extirpation followed by a single 90Strontium application. Eur J Ophthalmol 2008;18(3):327331
13 Kirwan JF, Constable PH, Murdoch1 IE, Khaw PT. Beta irradiation: new uses for an old treatment: a review. Eye 2003;17(2):207215
14 Kal HB, Veen RE, J rgenliemkSchulz IM. Doseeffect relationships for recurrence of keloid and pterygium after surgery and radiotherapy. Int
J Radiat Oncol Biol Phys 2009;74(1):245251 上一页 [1] [2] |
